Company intelligence / Profile preview
TaiMed Biologics
Neihu District, Taipei City, Taiwantaimedbiologics.com ↗
- Ownership
- Public · 4147
- Employees
- ~81
- Development stage
- Other
01
Overview
Commercializing Trogarzo® (ibalizumab) for multi-drug resistant HIV while advancing long-acting mAb combinations and exploring ADCs through strategic investments. Recent Phase IIa success with TMB-365/380 combination therapy.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodies(Antibody-Drug Conjugates via Marigold Therapeutics investment)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $454.4M
- Total revenue
- $18.7M
- Enterprise value
- $420M
Beyond the preview
Go deeper on TaiMed Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TaiMed Biologics.